Phaseline

Targets › NISCH

NISCH (Nischarin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2028.

Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. (UniProt, Q9Y2I1)

Open in Phaseline: the race on NISCH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vanderbilt University Medical CenterMoxonidine
Nischarin agonist
NISCHPhase 1ObesityDec 2028

Conditions

Obesity (1)

Modalities

small molecule (1)

Companies

Vanderbilt University Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.